MedPath

APELLIS PHARMACEUTICALS, INC

APELLIS PHARMACEUTICALS, INC logo
🇺🇸United States
Ownership
Public
Established
2008-01-01
Employees
706
Market Cap
$4.8B
Website
http://www.apellis.com

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

Phase 1
Completed
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
First Posted Date
2015-10-28
Last Posted Date
2021-01-11
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
23
Registration Number
NCT02588833
Locations
🇳🇿

Waikato Hospital, Hamilton, Waikato, New Zealand

🇲🇾

Hospital Ampang, Ampang, Selangor, Malaysia

🇹🇭

Ramathibodi Hospital, Bangkok, Thailand

and more 4 locations

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

Phase 2
Completed
Conditions
Geographic Atrophy
Interventions
Other: Sham Procedure
Drug: Pegcetacoplan
First Posted Date
2015-07-20
Last Posted Date
2020-10-06
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
246
Registration Number
NCT02503332
Locations
🇺🇸

The Gavin Herbert Eye Institute/UC Irvine, Irvine, California, United States

🇺🇸

University of Southern California - USC Eye Institute, Los Angeles, California, United States

🇺🇸

Associated Retinal Consultants, PC, Traverse City, Michigan, United States

and more 42 locations

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

Phase 1
Completed
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
First Posted Date
2015-06-03
Last Posted Date
2020-10-06
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
13
Registration Number
NCT02461771
Locations
🇺🇸

United States, Florida, Miami, Florida, United States

🇺🇸

United States, California, Beverly Hills, California, United States

🇦🇺

Australia, New South Wells, Parramatta, New South Wales, Australia

and more 1 locations

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Phase 1
Completed
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
First Posted Date
2014-10-15
Last Posted Date
2021-01-08
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT02264639
Locations
🇺🇸

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Lakes Research, Miami Lakes, Florida, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath